921 related articles for article (PubMed ID: 28986314)
21. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
[TBL] [Abstract][Full Text] [Related]
23. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
[TBL] [Abstract][Full Text] [Related]
24. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
25. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
27. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
[TBL] [Abstract][Full Text] [Related]
28. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
[TBL] [Abstract][Full Text] [Related]
30. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.
Mendez-Eirin E; Paniagua-Martín MJ; Marzoa-Rivas R; Barge-Caballero E; Grille-Cancela Z; Cañizares A; Naya-Leira C; Gargallo-Fernández P; Castro-Beiras A; Crespo-Leiro M
Transplant Proc; 2012 Nov; 44(9):2660-2. PubMed ID: 23146486
[TBL] [Abstract][Full Text] [Related]
31. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
[TBL] [Abstract][Full Text] [Related]
34. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
38. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
[TBL] [Abstract][Full Text] [Related]
39. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
40. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction.
Walker JK; Scholz LM; Scheetz MH; Gallon LG; Kaufman DB; Rachwalski EJ; Abecassis MM; Leventhal JR
Transplantation; 2007 Apr; 83(7):874-82. PubMed ID: 17460557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
